Cannabis Producers Look to
Differentiate-THC Therapeutics, Inc. (THCT)
May 21, 2019 -- InvestorsHub NewsWire -- via MicrocapSpeculators.com --
It’s been recently reported that some cannabis producers will have
trouble moving their crop, which is why it will be key to
differentiate their product from competitors. That’s why
we’re highlighting THC Therapeutics, Inc. (THCT).
THC Therapeutics, Inc. (THCT)
just made a major announcement; THCT announced Enzo Villani
was appointed a member of the company’s Board of Directors.
Mr. Villani is Co-Founder of Nasdaq Global Corporate Solutions
Group.
Mr. Villani has raised over $500 million in funding from
strategic investors, private equity, venture capital, family
offices and the public markets during his over twenty-year
career.
THCT’s dHydronator, can reduce moisture content
of cannabis to 10% in only 10-14 hours.
This is the same reason Aurora just signed a deal with
EnWave. THCT received patent protection on 20 claims
from the US patent office in March ’19 and will be using their
patented designs to carve out their piece of the legal cannabis
market expected to reach $146.4 billion by 2025.
Today we are highlighting: THC Therapeutics, Inc. (THCT),
Aphria, Inc. (APHA), GW Pharmaceuticals plc (GWPH),
The Green Organic Dutchman (TGODF), and Altria Group, Inc.
(MO).
THC Therapeutics, Inc. (THCT)
(Market Cap: $132.201M; Share Price: $9.60)
has developed a sanitizing herb dryer, The dHydronator®.
Their laboratory-proven product is specifically designed for drying
and sanitizing freshly harvested cannabis and herbs.
THCT’s product has been tested by two independent
laboratories. The testing covered over 6 strains and 9
independent tests to confirm the findings. Over the 9
tests and 6 strains, there was a 4% average increase of THC-A*.
The US patent office has accepted ALL 20 claims for The
dHydronator®. The company has received full
patent protection for the
dHydronator®. Start your research
today on THCT.
________
Aphria Inc. (APHA)
(Market Cap: $1.78B; Share Price: $7.03) shares
fell after the Canadian cannabis company reported fiscal
third-quarter results. It posted a C$108.2 million ($81.1
million) loss for its fiscal third quarter, or 43 cents a
share, after a profit of C$12.9 million, or 8 cents a share, in the
same period a year ago. Revenue climbed to C$73.6 million
from C$10.3 million in the first full quarter of Canadian legal
cannabis. But the company sold less cannabis than a year
ago—kilograms sold fell to 2,636.5 from 3,408.9, while the average
retail selling price for medical cannabis increased to C$8.03 per
gram from C$7.51, primarily because of higher oil sales.
In April, it announced that the previously announced take-over
bid (the "Offer") by Green Growth Brands Inc. ("GGB") has failed to
meet the statutory minimum tender condition and has now expired and
is terminated. As previously announced on April 15, 2019,
the Company entered into a definitive agreement with GGB to
accelerate the expiry date of the Offer to April 25, 2019, as well
as to terminate certain arrangements with GA Opportunities Corp.
("GAOC") for consideration of $89.0 million payable on future dates
as set out in the April 15th press release. The Offer is now
expired and terminated and no longer open to any Aphria shareholder
to tender their shares. Accordingly, GGB will not be taking up any
securities that may have been tendered to the Offer. GGB will
promptly return to the securityholder any Aphria shares tendered
and not withdrawn during the period from the commencement of the
Offer up to the expiry time of the Offer.
_________
GW Pharmaceuticals plc (GWPH)
(Market Cap: $5.597B; Share Price: $182.21), the
world leader in the development and commercialization of
cannabinoid prescription medicines, recently announced the
appointment of Darren Cline as its new U.S. Chief Commercial
Officer. Mr. Cline will lead the Epidiolex® U.S.
commercial organization and is expected to start on April 22,
2019.
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on
discovering, developing, and commercializing cannabinoid
prescription medicines using botanical extracts derived from the
Cannabis plant. Its lead product is Epidiolex, an oral
medicine for the treatment of refractory childhood epilepsies, as
well as for the treatment of Dravet syndrome, Lennox-Gastaut
syndrome, tuberous sclerosis complex, and infantile spasms.
GW commercialized the world's first plant-derived cannabinoid
prescription drug, Sativex® (nabiximols), which is approved for the
treatment of spasticity due to multiple sclerosis in numerous
countries outside the United States and for which the company is
now planning a U.S. Phase 3 trial. The company has a deep
pipeline of additional cannabinoid product candidates which
includes compounds in Phase 1 and 2 trials for epilepsy,
glioblastoma, and schizophrenia.
_________
The Green Organic Dutchman (TGODF)
(Market Cap: $774.832M; Share Price: $2.91),
recently participated in Virtual Investor Conferences.
The Green Organic Dutchman is an Ontario, Canada, based marijuana
company that was IPO’d in spring 2018 and is currently valued at
$957 million.
The Green Organic Dutchman expects that its production capacity
will be 170,000 kg marijuana a year, based on several deals that
have expanded the company’s asset base during 2018.
This includes the June 2018 acquisition of a facility
(approximately 280,000 square foot) that The Green Organic Dutchman
plans to use for producing marijuana-containing edible products and
marijuana-infused beverages. It recently announced that
effective March 25th, 2019 sales of certified-organic cannabis have
started with national distribution to medical patients. The
Growers' Circle is a select group of patients across Canada now
receiving TGOD's first certified-organic flower.
_________
Altria Group, Inc. (MO)
(Market Cap: $97.344B; Share Price:
$52.03) announced that it has received a
request for additional information (Second Request) from the U.S.
Federal Trade Commission relating to its investment in JUUL Labs,
Inc. that closed in December 2018.
Altria Group, Inc., through its subsidiaries, manufactures and
sells cigarettes, smokeless products, and wine in the United
States. It offers cigarettes primarily under the Marlboro
brand; cigars principally under the Black & Mild brand; and
moist smokeless tobacco products under the Copenhagen, Skoal, Red
Seal, and Husky brands. The company also produces and sells
varietal and blended table wines, and sparkling wines.
Legal Disclaimer:
This article was written by Regal Consulting, LLC (“Regal
Consulting”). Regal Consulting has agreed to a three-month
term consulting agreement with THCT dated 2/14/18. The
agreement calls for 50,000 restricted shares of THCT per month.
This agreement has been amended to $20,000 per month, and 55,000
shares per month and extended for twelve months ending 3/18/2020.
All payments were made directly by THC Therapeutics, Inc. to Regal
Consulting, LLC. to provide investor relations services, of which
this article is a part of. Regal Consulting also paid one
thousand dollars cash to microcapspeculators.com to distribute this
article. Regal Consulting may have a position in the securities
mentioned in this article at the time of publication, and may
increase or decrease its position without notice. This
article is based on public information and the opinions of Regal
Consulting. THCT was given an opportunity to edit this article.
This article contains forward-looking statements that are subject
to certain risks and uncertainties that could cause actual results
to differ materially from any results predicted herein. Regal
Consulting is not registered with any financial or securities
regulatory authority, and does not provide or claim to provide
investment advice.
http://www.regalconsultingllc.com/full
legal disclaimer/
Full Legal Disclaimer Click Here.
Contact Information:
Company Name: ACR Communication LLC.
Contact Person: Media Manager
Email: info@microcapspeculators.com
Phone: 1-702-720-6310
Country: United States
THC Therapeutics (CE) (USOTC:THCT)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
THC Therapeutics (CE) (USOTC:THCT)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024